ID: ALA3542190

Max Phase: Preclinical

Molecular Formula: C23H17FN6O3

Molecular Weight: 444.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cc(F)cc(c32)C1

Standard InChI:  InChI=1S/C23H17FN6O3/c24-13-7-12-10-29(23(25)33)6-5-28-11-15(14(8-13)20(12)28)18-19(22(32)27-21(18)31)16-9-26-17-3-1-2-4-30(16)17/h1-4,7-9,11H,5-6,10H2,(H2,25,33)(H,27,31,32)

Standard InChI Key:  ALGBDYQAAODVQK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 444.43

Molecular Weight (Monoisotopic): 444.1346

AlogP: 1.89

#Rotatable Bonds: 2

Polar Surface Area: 114.73

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.82

CX Basic pKa: 5.27

CX LogP: 0.53

CX LogD: 0.53

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.46

Np Likeness Score: -1.25

References

1. Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC..  (2013)  Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.,  41  (4): [PMID:23305709] [10.1124/dmd.112.048488]

Source

Source(1):

• Scientific Literature